礼来宣布替尔泊肽注射液多剂量预装笔在中国正式上市

Core Viewpoint - Eli Lilly announced the official launch of Mounjaro® (tirzepatide injection multi-dose prefilled pen) in China, targeting adult patients with type 2 diabetes (T2DM) who have inadequate blood sugar control despite diet, exercise, and treatment with metformin and/or sulfonylureas [1] Group 1 - Mounjaro is the first and currently the only approved weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist for T2DM and long-term weight management [1]